Cardinale D et al., 2015-06-02: Prospective cohort of 2,625 patients receiving anthracyclines at two Milan institutions. Cardiotoxicity incidence was 9%, almost all within the first year, with 71% partial and 11% full recovery after heart-failure therapy.
The median time elapsed between the end of chemotherapy and cardiotoxicity development was 3.5 (quartile 1 to quartile 3, 3-6) months. In 98% of cases (n=221), cardiotoxicity occurred within the first year.
Abstract (Methods and Results)
Cardinale D et al., 2015-06-02: Prospective cohort of 2,625 patients receiving anthracyclines at two Milan institutions. Cardiotoxicity incidence was 9%, almost all within the first year, with 71% partial and 11% full recovery after heart-failure therapy. Comparator: none – single-arm prospective cohort with serial LVEF; cardiotoxicity defined as LVEF fall >10 points to <50%. Funder/COI not in the abstract. The 9% figure is the incidence of the protocol-defined cardiotoxicity endpoint, not of symptomatic heart failure; the same paper reports 11% full and 71% partial recovery, which is the counterweight the book omits when it implies permanent damage. Study type: uncontrolled series.
